Kymera实验性湿疹药物试验加速 股价上涨

路透中文06-25 19:50
BUZZ-Kymera实验性湿疹药物试验加速 股价上涨

6月25日 - ** 药物研发公司Kymera Therapeutics（KYMR.O）的股价在盘前交易中上涨7.8%，至107.8美元

** 该公司表示，其用于治疗中重度特应性皮炎的实验性疗法KT-621的中期临床试验已完成受试者招募

** 患者入组时间早于预期，这使得Kymera能够将主要研究结果公布时间提前至2026年底——比此前2027年年中这一预期提前了六个月——KYMR

** 公司表示预计将于2027年年中启动晚期临床试验

** RBC资本市场表示：“时间表的加速应使KYMR重新进入投资者2026年的关注视野，我们继续看好621的强劲前景以及股价的上行潜力”

** “这体现了研究人员和患者对这一新作用机制以及作为Regeneron公司Dupixent口服替代方案的期待”——摩根大通

** 截至上一交易日收盘，该股年内累计上涨28.4%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment